Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.78 |
| ▸ | KDR | P35968 | 8/20 | 0.78 |
| ▸ | LCK | P06239 | 5/20 | 0.78 |
| ▸ | RET | P07949 | 3/20 | 0.76 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.76 |
| ▸ | FLT1 | P17948 | 1/20 | 0.76 |
| ▸ | GAK | O14976 | 1/20 | 0.76 |
| ▸ | STK10 | O94804 | 1/20 | 0.76 |
| ▸ | FLT3 | P36888 | 1/20 | 0.76 |
| ▸ | JAK3 | P52333 | 1/20 | 0.76 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.76 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.76 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.76 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.76 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.76 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.76 |
| ▸ | CLK1 | P49759 | 1/20 | 0.75 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.75 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.69 |
| ▸ | KIF5B | P33176 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1507577 | 0.99 | EGFR (0.78) | EGFRKDRLCKRETRIPK2 | |
| SCHEMBL31067708 | 0.91 | KDR (0.82) | EGFRKDRRETRIPK2GAK | |
| SCHEMBL5467825 | 0.87 | EGFR (1.00) | EGFRKDRLCKRETRIPK2 | |
| SCHEMBL5473778 | 0.87 | EGFR (0.80) | EGFRKDRLCKRETRIPK2 | |
| SCHEMBL3533221 | 0.87 | EGFR (0.80) | EGFRKDRLCKRETRIPK2 | |
| SCHEMBL5472599 | 0.87 | EGFR (1.00) | EGFRKDRLCKRETRIPK2 | |
| SCHEMBL1387182 | 0.86 | EGFR (0.94) | EGFRKDRLCKRETRIPK2 | |
| SCHEMBL5477771 | 0.86 | KDR (1.00) | EGFRKDRLCKRETRIPK2 | |
| Hydrochloric Acid SCHEMBL5473795 | 0.86 | EGFR (0.80) | EGFRKDRLCKRETRIPK2 | |
| Whi-P131 SCHEMBL29295 | 0.86 | EGFR (1.00) | EGFRKDRLCKRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513267-B2 | 4-anilinoquinazoline derivatives with adenosine-kinase inhibitor properties | UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) | 2013-08-20 | — | — | US | disclosed |
| EP-1737832-B1 | 4-ANILINOQUINAZOLINE DERIVATIVES WITH ADENOSINE-KINASE INHIBITORY PROPERTIES | UNICAMP (BR) | 2011-12-14 | — | — | EP | disclosed |
| US-20070060600-A1 | 4-Anilinequinazolines with adenosine-kiase inhibitor properties | UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) | 2007-03-15 | — | — | US | disclosed |
| US-7105669-B1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2006-09-12 | — | — | US | disclosed |
| US-7081461-B1 | Quinazoline compounds and pharmaceutical compositions containing them | ASTRAZENECA AB (SE) | 2006-07-25 | — | — | US | disclosed |
| EP-0748219-B8 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN INC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1218357-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-04-06 | — | — | EP | disclosed |
| US-6638939-B2 | Anticancer agents | PARKER HUGHES INSTITUTE | 2003-10-28 | — | — | US | disclosed |
| US-20020137757-A1 | Quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2002-09-26 | — | — | US | disclosed |
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | PARKER HUGHES INSTITUTE | 2002-08-15 | — | — | US | disclosed |
| WO-2000056338-A1 | QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | disclosed |
| US-5981569-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION AND PARTICULARLY KDR/FLK-1 RECEPTOR SIGNAL TRANSDUCTION IN ORDER TO REGULATE AND/OR MODULATE VASCULOGENESIS AND ANGIOGENESIS; TREATMENT OF CANCER, DIABETES, HEMANGIOMA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-11-09 | — | — | US | disclosed |
| EP-0748219-A4 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN INC (US) | 1999-06-16 | — | — | EP | disclosed |
| US-5849742-A | Compounds for the treament of disorders related to vasculogenesis and/or angiogenesis | SUGEN INC. (US) | 1998-12-15 | — | — | US | disclosed |
| US-5792771-A | FOR TREATING TUMORS, VASCULAR SYSTEM DISORDERS, DIABETES, DIABETIC RETINOPATHY, RHEUMATOID ARTHRITIS AND HEMANGIOMA | SUGEN, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5763441-A | ADMINISTERING TO THE PATIENT SUFFERING FROM DIABETES, GLIOMA, HEMANGIOMA, KAPOSI'S SARCOMA, OVARIAN/BREAST/PANCREATIC/COLON AND PROSTATE CANCER A BENZO(G)QUINOXALINE COMPOUNDS | SUGEN, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5712395-A | BENZO(G)QUINOXALINE | YISSUM RESEARCH DEVELOPMENT CORP. (IL) | 1998-01-27 | — | — | US | disclosed |
| EP-0748219-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | Sugen, Inc. (US) | 1996-12-18 | — | — | EP | disclosed |
| CN-1137037-A | Quinazoline derivatives | PFIZER (US) | 1996-12-04 | — | — | CN | disclosed |
| WO-1995021613-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | CMA1, MAST3, MAST1 | EGFR 3336/4885KDR 2810/4885LCK 525/4885 |
| US-20070060600-A1 | 4-Anilinequinazolines with adenosine-kiase inhibitor properties | ADK, AK1, ADORA3 | EGFR 3142/4885KDR 1289/4885LCK 860/4885 |
| US-20020137757-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | EGFR 1931/4885KDR 3004/4885LCK 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.